Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (713)	2/18/1998 6:17:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 1432

<<Thanks again for your lucid, well researched, highly empirical analysis as usual.>> Thank you. Based on my analysis of the company, I consider it grossly overvalued. The company has miniscule cash in the bank, no real assets, and its lead product candidate- Hextend, is not any better than Hespan. Claims that Hextend will compete with albumin are ludicrous and false. Hespan's market is relatively small- and there is really no reason to switch to Hextend. Despite fraudulent claims by Biotime's management and various stock promoters, there is absolutely no reason to buy and hold this stock. Its current market cap of $200,000,000 will quickly deteriorate.